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Mitochondrial damage and dysfunction are common hallmarks for neurodegenerative
disorders, including Alzheimer, Parkinson, Huntington diseases, and the motor neuron
disorder amyotrophic lateral sclerosis. Damaged mitochondria pivotally contribute to
neurotoxicity and neuronal cell death in these disorders, e.g., due to their inability to
provide the high energy requirements for neurons, their generation of reactive oxygen
species (ROS), and their induction of mitochondrion-mediated cell death pathways.
Therefore, in-depth analyses of the underlying molecular pathways, including cellular
mechanisms controlling the maintenance of mitochondrial function, is a prerequisite
for a better understanding of neurodegenerative disorders. The yeast Saccharomyces
cerevisiae is an established model for deciphering mitochondrial quality control
mechanisms and the distinct mitochondrial roles during apoptosis and programmed
cell death. Cell death upon expression of various human neurotoxic proteins has been
characterized in yeast, revealing neurotoxic protein-specific differences. This review
summarizes how mitochondria are affected in these neurotoxic yeast models, and how
they are involved in the execution and prevention of cell death. I will discuss to which
extent this mimics the situation in other neurotoxic model systems, and how this may
contribute to a better understanding of the mitochondrial roles in the human disorders.
Keywords: mitochondria, mitochondrial dysfunction, mitochondrial quality control, neurodegeneration,
neurotoxicity, cell death, Saccharomyces cerevisiae
INTRODUCTION
Mitochondria are important organelles; they produce most of
the ATP via oxidative phosphorylation, they are involved in
lipid and phospholipid metabolism, in the biosynthesis of essen-
tial intermediates, including heme and iron-sulfur clusters, and
they contribute to various cellular stress responses, includ-
ing programmed cell death (Nunnari and Suomalainen, 2012).
Functional mitochondria are essential for neurons, which have an
extreme high demand for energy in their cell bodies and synapses
(Nunnari and Suomalainen, 2012). Therefore, it is evident that
neurons are extremely vulnerable against mitochondrial damage.
Mitochondrial damage is a hallmark for Alzheimer, Parkinson,
Huntington diseases, and amyotrophic lateral sclerosis (Martin,
2011; Correia et al., 2012; Cozzolino et al., 2012). Affected neu-
rons suffer from ATP depletion, loss of respiratory capacity,
elevated levels of reactive oxygen species (ROS), the induction of
mitochondrion-specific cell death pathways, and immotile mito-
chondria, which fail to localize to the sites with increased energy
demands, such as synapses (Martin, 2011; Correia et al., 2012;
Cozzolino et al., 2012) (Figure 1). Mitochondrial damage in neu-
rons can be described by (1) mutations in the mitochondrial DNA
(mtDNA), (2) the loss of the mitochondrial membrane poten-
tial, (3) the loss of mitochondrial protein import and protein
biosynthesis, (4) reduced activities of enzymes of the mitochon-
drial respiratory chain and the TCA cycle, (5) increased leakage
of electrons from the respiratory chain generating ROS, (6)
the loss of mitochondrial motility, (7) the destruction of the
mitochondrial network, and (8) the rupture of the mitochon-
drial outer and inner membranes, leading (9) to the release of
mitochondrial pro-death factors, including cytochrome c (Cyt. c),
apoptosis-inducing factor, or endonuclease G.
Nature developed many mechanisms to prevent and repair
mitochondrial damage or to remove damaged mitochondria
(Figure 1): (1) the dynamic fusion and fission of mitochondria
enables the maintenance of intact mtDNA (Westermann, 2010;
Hori et al., 2011), (2) the phospholipid turnover between the
ER and mitochondria allows for the rejuvenation of mitochon-
drial membranes (Fujimoto and Hayashi, 2011), (3) retrograde
signaling senses mitochondrial damage, eliciting a nuclear tran-
scriptional response to counteract mitochondrial damage (Liu
and Butow, 2006; Pellegrino et al., 2012), (4) mitochondrial
biogenesis leads to the replenishment of damaged mitochon-
dria and its components (Michel et al., 2012), (5) mitochon-
drial protein quality control is guaranteed by chaperones and
the proteolytic machinery, including the proteasome-dependent
mitochondrion-associated degradation (MAD) of mitochondrial
outer membrane proteins (Heo et al., 2010; Taylor and Rutter,
2011), the proteolytic degradation of proteins of the intermem-
brane space, the inner membrane, and the matrix (Fischer et al.,
2012; Rugarli and Langer, 2012), and (6) removal of dam-
aged mitochondria occurs via mitochondrion-specific autophagy
(mitophagy) (Kanki and Klionsky, 2010). Thus, the detailed
analysis of mitochondrial damage, and the mechanisms counter-
acting mitochondrial damage and its devastating consequences
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FIGURE 1 | Mitochondrial dynamics, damage and degradation,
and mitochondrion-dependent cell death upon neurotoxic protein
expression in yeast. Mitochondria are part of a network promoted by fusion
or are fragmented into individual organelles by fission. They are transported
along the cytoskeleton. Damaged mitochondria are targeted by cytoplasmic
proteins, including Ybh3 and Mmi1, produce ROS or release proteins into the
cytosol, including cytochrome c, Aif1, and Nuc1, triggering apoptosis and
necrosis. Mitophagy and proteasome-dependent pathways remove damaged
mitochondria, and mitochondrial biogenesis and retrograde signaling are
involved in the replenishment and repair of the mitochondrial pool,
respectively. Neurotoxic proteins trigger mitochondrial damage and cell
death: they could interfere with mitochondrial fusion, fission, and motility, or
could interrupt with mitochondrion degradation triggering “lethal mitophagy”,
or could directly affect mitochondrial function.
for neurons, is of high importance for a better understanding of
neurodegenerative disorders.
Yeast is an established model for dissecting conserved mecha-
nisms of programmed cell death including apoptosis and necrosis
(Carmona-Gutierrez et al., 2010). In yeast, cytotoxicity can eas-
ily be measured by complementary methods (Braun et al., 2010).
Growth assays measure growth rates on agar plates or in liquid
cultures, clonogenic survival assays measure the ability of yeast
cells to form new colonies, and necrosis and apoptosis can be
discriminated by analyzing cells for morphological markers of
these subroutines of cell death. The importance of mitochon-
dria in distinct cell death scenarios is well described in yeast
(Eisenberg et al., 2007; Pereira et al., 2008; Guaragnella et al.,
2012) (Figure 1). The mitochondrial permeabilization and the
consequent release of the mitochondrial cell death proteins Cyt. c,
yeast apoptosis-inducing factor (Aif1), or yeast endonuclease
G (Nuc1) was observed (Ludovico et al., 2002; Wissing et al.,
2004; Büttner et al., 2007; Pereira et al., 2007). ROS are pro-
duced from the mitochondrial respiratory chain, including the
internal NADH dehydrogenase (Ndi1) and complex III (Braun
et al., 2006, 2011; Li et al., 2006). Cytoplasmic proteins are
recruited to themitochondrial outer membrane, such as the BH3-
only protein Ybh3 and the microtubule-associated protein Mmi1
(Rinnerthaler et al., 2006; Büttner et al., 2011). Mitochondrial
quality control mechanisms and their influence on cell survival
and aging have been intensively examined in yeast (Westermann,
2010; Braun and Westermann, 2011; Müller and Reichert, 2011;
Fischer et al., 2012; Nunnari and Suomalainen, 2012; Rugarli
and Langer, 2012). Indeed, our knowledge about mitochon-
drial dynamics, including mitochondrial fusion, fission, motility,
degradation, and protein quality control is strongly influenced
by data originally obtained in yeast, and later validated in other
organisms, including humans. In the recent years, many yeast
models have been established to analyze the influence of human
neurotoxic protein expression on yeast cell survival, including
models for Alzheimer, Parkinson, Huntington, andmotor neuron
disorders (Gitler, 2008; Miller-Fleming et al., 2008; Winderickx
et al., 2008; Bharadwaj et al., 2010; Braun et al., 2010; Khurana
and Lindquist, 2010; Bastow et al., 2011; De Vos et al., 2011;
Mason and Giorgini, 2011).
Here, I summarize how mitochondria are damaged in these
neurotoxic yeast cell death models, which role they play in the
execution of cell death, and which mitochondrial quality con-
trol mechanisms potentially influence cytotoxicity. Further, I will
critically discuss the similarities and discrepancies between the
neurotoxic yeast models, and the animal and cell culture disease
models.
NEUROTOXIC YEAST MODELS
ALZHEIMER DISEASE (AD) AND FRONTOTEMPORAL LOBAR
DEGENERATION (FTLD-tau)
AD is the most prevalent form of age-related dementia
(Querfurth and Laferla, 2010). It is characterized by a progres-
sive deterioration, concomitant with behavior impairments and
deficits in language and visuospatial skills (Querfurth and Laferla,
2010). Synaptic loss and neuronal decline can be observed in
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affected brain regions, including the hippocampus and the cortex
(Querfurth and Laferla, 2010). The accumulation of extracellu-
lar senile plaques and intracellular aggregates, composed of the
β-amyloid peptide, and the intracellular accumulation of neu-
rofibrillary tangles comprising hyperphosphorylated variants of
the microtubule-associated protein tau contribute to the progres-
sion of AD (Laferla et al., 2007; Benilova et al., 2012; Mandelkow
and Mandelkow, 2012).
FTLD is the second most common form of early onset demen-
tia after AD (Sieben et al., 2012). It is characterized by a selective
atrophy of the frontal and anterior temporal lobes of the brain,
leading to disturbances of behavior and personality (Sieben et al.,
2012). Intracellular accumulation of the hyperphosphorylated
protein tau is a hallmark of one subtype of FTLD, called FTLD-
tau (Sieben et al., 2012). Mutations in MAPT, the gene encoding
tau, trigger neuronal degeneration and FTLD-tau (Sieben et al.,
2012). In order to elucidate conserved mechanisms of AD/FTLD-
relevant cytotoxicity, yeast models expressing AD-associated
β-amyloid, and AD/FTLD-associated wild-type and mutant tau
were established (Bharadwaj et al., 2010; De Vos et al., 2011).
AD-associated β-amyloid triggers cytotoxicity and mitochondrial
damage upon localization to the secretory pathway
Several yeast AD models for dissecting the cytotoxic role of intra-
cellular β-amyloid have been established (Bharadwaj et al., 2010;
Treusch et al., 2011; D’Angelo et al., 2012). Whereas cytoso-
lic β-amyloid and β-amyloid fusion proteins did not exert a
marked cytotoxicity on yeast, two recent studies demonstrated
that directing β-amyloid to the secretory pathway resulted in
significant cytotoxicity, as measured by growth assays (Treusch
et al., 2011; D’Angelo et al., 2012) (Table 1). In these models
β-amyloid oligomerization could be observed, and aggregation
and growth deficits were increased expressing AD-associated
mutant β-amyloid (Treusch et al., 2011; D’Angelo et al., 2012).
Although β-amyloid-triggered cytotoxicity was elicited in the
secretory pathway, there are some hints that mitochondria were
damaged and involved in the execution of cytotoxicity (D’Angelo
et al., 2012). β-amyloid-expressing cells demonstrated decreased
growth rates on obligatory respiratory growth media, and the
oxygen consumption was markedly reduced in these cells under
these conditions. Since the decrease in oxygen consumption
preceded the observed growth deficits, these data suggest that
mitochondrial impairment is causative for β-amyloid-triggered
cytotoxicity. In a genome-wide overexpression screen to identify
enhancers and suppressors of β-amyloid-triggered cytotoxicity
(growth assays), PET111 and SLS1 encoding two mitochondrion-
associated translation regulators were found as enhancers, and
RTG3, encoding a transcriptional activator of the retrograde
response, a response to counteract mitochondrial damage (Liu
and Butow, 2006), was identified as suppressor (Treusch et al.,
2011). Further studies will have to show, in which way mitochon-
drial protein translation and the retrograde response are involved
in modulating β-amyloid-triggered cytotoxicity. It will also be of
interest to investigate how β-amyloid expression can result in the
potential mitochondrial damage in yeast, and whether it induces
apoptotic and/or necrotic cell death. Although part of β-amyloid,
which was directed to the secretory pathway, was later found to
be cytosolic (D’Angelo et al., 2012), it remains an open question
whether β-amyloid directly or indirectly affects mitochondrial
function, and therewith influence cell survival.
Oxidative stress and mitochondrial dysfunction enhance
aggregation of AD/FTLD-associated wild-type and mutant tau in
yeast
Expression of FTLD-associated wild-type and mutant (P301L)
tau did not trigger cytotoxicity in yeast, although it increased
growth deficits upon co-expression with PD-associated
α-synuclein (Zabrocki et al., 2005) (Table 1). Human tau
formed sarkosyl-insoluble aggregates, which were highly phos-
phorylated by the yeast tau kinases Mds1 and Pho85 (Vandebroek
et al., 2005, 2006; Vanhelmont et al., 2010). Treatment with fer-
rous sulfate, which increases ROS production, resulted in a
significant increase in pathological tau aggregates in yeast cells
expressing tau (Vanhelmont et al., 2010). This phenomenon was
increased with FTLD-associated mutant (P301L) tau compared
to wild-type tau, and it was independent of the phosphorylation
status of tau, suggesting that ROS-increased tau aggregation
acted mainly in parallel to tau phosphorylation (Vanhelmont
et al., 2010). Increased pathological tau aggregates were also
observed in yeast cells lacking the mitochondrial antioxidant
enzyme superoxide dismutase 2 (sod2), and in yeast cells
lacking mtDNA (rim1) (Vanhelmont et al., 2010). These
data suggest that mitochondrially localized ROS and mito-
chondrial dysfunction contribute to tau pathology in yeast
(Vanhelmont et al., 2010; De Vos et al., 2011).
Yeast AD models recapitulate key features observed in animal AD
models and in AD patients
Mitochondrial damage and dysfunction are characteristics of
both familiar and sporadic AD (Correia et al., 2012). Decreased
abundances and activities of the pyruvate dehydrogenase com-
plex, the TCA cycle enzymes, andmitochondrial respiratory chain
complexes were observed in AD patients, animal and cell culture
AD models (Correia et al., 2012). These data point to decreased
mitochondrial activities and a consequent loss in energy supply
(Correia et al., 2012). Yeast cells expressing β-amyloid demon-
strated decreased oxygen consumption and decreased growth
rates on obligatory respiratory growth media (D’Angelo et al.,
2012), mimicking the energy hypometabolism observed in AD
patients and other model systems. In AD patients and higher AD
models, high levels of lipid and protein oxidation, as well as high
incidences of mtDNAmutations hint to increased levels of oxida-
tive stress in affected neurons (Correia et al., 2012). Oxidative
stress has been suggested to facilitate pathological aggregation
of β-amyloid and tau, which are then believed to further dam-
age mitochondria in a vicious cycle (Swerdlow et al., 2010;
Leuner et al., 2012). Although it remains undetermined whether
β-amyloid or tau expression in yeast triggers ROS production,
chemically induced oxidative stress in yeast cells expressing tau
markedly increased its conversion into pathological tau aggregates
(Vanhelmont et al., 2010). Thus, high levels of oxidative stress,
e.g., due to damaged mitochondria, may contribute to increased
levels of pathological tau, accelerating cell death (De Vos et al.,
2011).
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Since β-amyloid was found to directly interact with mito-
chondria in higher AD models, these data suggest that at least
part of the mitochondrial damage might be elicited by a detri-
mental interaction between the disease peptide and the organelle
(Correia et al., 2012). In fact, in yeast β-amyloid was also iden-
tified in the cytosol (D’Angelo et al., 2012). Whether a direct
interaction between β-amyloid and mitochondria occurs remains
unknown. In animal and cell culture AD/FTLDmodels expressing
AD-associated β-amyloid or FTLD-associated tau, mitochondrial
dynamics was demonstrated to be aberrantly altered: abnormal
mitochondrial morphology, and altered mitochondrial fission
and fusion, as well as decreased mitochondrial motility and
increased mitophagy were observed (Correia et al., 2012; Schulz
et al., 2012). Since the pathways regulating mitochondrial dynam-
ics and mitochondrial quality control are conserved from yeast
to humans (Westermann, 2010; Fischer et al., 2012; Rugarli and
Langer, 2012), yeast may help to elucidate how these pathways
influence cytotoxicity upon expression of β-amyloid or tau.
PARKINSON DISEASE (PD)
PD is the most prevalent age-related movement disorder char-
acterized by a progressive loss of dopaminergic neurons in the
substantia nigra pars compacta (Lees et al., 2009). This results
in a loss of the neurotransmitter dopamine in the striatum and
consequently impairs with normalmotor function leading to rest-
ing tremor, bradykinesia and rigidity (Lees et al., 2009). In most
familiar and sporadic cases, PD is associated with Lewy bodies,
i.e., intracellular cytoplasmic aggregates composed of the protein
α-synuclein (Uversky, 2007). Consistently, missense mutations in
the SNCA gene, resulting in the expression of α-synuclein vari-
ants (A30P, A53T, E46K), as well as duplication and triplication of
SNCA, leading to elevated α-synuclein levels, are causative for PD
in some familiar forms of the disorder (Uversky, 2007).Mutations
in other genes, including genes encoding the leucine-rich repeat
kinase 2 (LRRK2), the E3 ubiquitin ligase parkin, the chaper-
one DJ-1, the mitochondrial PTEN-induced putative kinase 1
(PINK1), and the lysosomal ATPase ATP13A2 also lead to PD
(Dehay and Bezard, 2011). Numerous disease models either over-
expressing or deleting these disease-associated genes have been
established, in order to describe common and distinct pathways
relevant for PD progression (Dehay and Bezard, 2011).
Overexpression of α-synuclein in yeast results in cytotoxicity, and
mitochondrion-dependent programmed cell death
Yeast cells overexpressing wild-type and disease-associated
α-synuclein demonstrated growth deficits and age-dependent loss
of clonogenic cell survival (Willingham et al., 2003; Flower et al.,
2005; Witt and Flower, 2006; Büttner et al., 2008; Lee et al., 2008)
(Table 1). α-Synuclein-triggered cytotoxicity in yeast was char-
acterized by increased levels of ROS, and by the emergence of
morphological markers of both apoptosis and necrosis (Flower
et al., 2005; Büttner et al., 2008; Su et al., 2010). Mitochondria are
critically damaged upon α-synuclein expression: (1) The mito-
chondrial network was fragmented (Sampaio-Marques et al.,
2012), (2) mitochondria were found to be abnormally swollen
(Su et al., 2010), (3) Cyt. c was released from mitochondria
into the cytosol (Flower et al., 2005), (4) α-synuclein-expressing
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cells treated with the proteasome inhibitor lactacystin demon-
strated loss of mitochondrial membrane potential (Lee et al.,
2008), and (5) mRNA profiling revealed that 60% of the
downregulated genes encode proteins localized to mitochon-
dria (Yeger-Lotem et al., 2009). Mitochondrial damage piv-
otally contributes to α-synuclein-triggered cytotoxicity, because
α-synuclein expression in ρ0 cells, which lack mtDNA and
are devoid of respiratory competent mitochondria, significantly
relieved the loss of cell survival, reduced the number of apoptotic
and necrotic cells and markedly decreased ROS levels (Büttner
et al., 2008). Mitochondrially produced ROS are important in
α-synuclein-triggered cytotoxicity: (1) Deletion of SOD2 encod-
ing the mitochondrial antioxidant enzyme superoxide dismu-
tase 2 markedly increased α-synuclein-triggered growth deficits
(Willingham et al., 2003), (2) α-synuclein-expressing yeast cells
were hypersensitive against oxidative stress (clonogenic cell sur-
vival assay upon hydrogen peroxide treatment) (Flower et al.,
2005), and (3) α-synuclein-triggered ROS accumulation could
efficiently be suppressed with the antioxidant glutathione (Flower
et al., 2005). In another study treatment of α-synuclein-expressing
cells with the antioxidantsN-acetylcysteine, riboflavin, and mela-
tonin did not show marked suppression of cytotoxicity (plasma
membrane integrity and growth assays) (Su et al., 2010), suggest-
ing that ROS rather accelerate α-synuclein-triggered cytotoxicity
but are not essential for it.
Indirect mechanisms result in mitochondrial damage upon
α-synuclein expression in yeast
α-Synuclein did not localize to yeast mitochondria, neither in cul-
tures with intermediate nor in cultures with high expression levels
of this protein (Gitler et al., 2008; Su et al., 2010). These data
suggest that α-synuclein does not directly induce mitochondrial
damage by mislocalizing to this organelle, as was discussed earlier
(Witt and Flower, 2006), but that mitochondria are impaired in
more indirect ways (Su et al., 2010). In fact, high expression levels
of α-synuclein triggered defects in ER homeostasis in yeast (Gitler
et al., 2008). This could have detrimental effects on the phos-
pholipid turnover from the ER to and from the mitochondrial
membranes (Fujimoto and Hayashi, 2011), thereby damaging
mitochondrial membranes (Su et al., 2010). Impaired ER traffick-
ing could also impair mitophagy, resulting in the accumulation
of damaged mitochondria (Su et al., 2010). Further studies will
be needed to shed light into cellular mechanisms affecting yeast
mitochondria during α-synuclein expression.
Mitophagy determines α-synuclein-triggered cytotoxicity in yeast
Using an approach combining data from mRNA profiling of
α-synuclein-expressing cultures with data from genetic sup-
pressor screens searching for modifiers of α-synuclein-triggered
cytotoxicity (growth assays) predicted the target of rapamycin
(TOR) pathway, as a modulator of α-synuclein-triggered cyto-
toxicity (Yeger-Lotem et al., 2009). Indeed, addition of the
TOR-inhibitor rapamycin markedly enhanced the growth deficits
elicited by α-synuclein (Yeger-Lotem et al., 2009). Since inac-
tivation of the TOR pathway induces autophagy-related path-
ways, these data gave first hints, that enhancing autophagy could
be harmful for cultures expressing α-synuclein. Consistently,
both rates of autophagy and mitochondrion-specific autophagy
(mitophagy) were significantly increased upon α-synuclein
expression (Sampaio-Marques et al., 2012). Pharmacological
inhibition of autophagy (and mitophagy) by treatment with
chloroquine markedly extended chronological life span of
yeast cells expressing α-synuclein (Sampaio-Marques et al.,
2012). Notably, inhibition of mitophagy alone was sufficient
to relieve α-synuclein-triggered cytotoxicity (Sampaio-Marques
et al., 2012): yeast cultures lacking the mitophagy-specific genes
ATG11 and ATG32 demonstrated loss of mitophagy upon expres-
sion of α-synuclein, concomitant to markedly increased chrono-
logical life spans, significantly reduced incidences of morphologi-
cal and metabolic markers of cell death, markedly decreased ROS
levels, and the restoration of the mitochondrial network. These
data suggest that mitophagy, a per se protective pathway to remove
damaged mitochondria, can exert lethal functions in yeast upon
high levels of α-synuclein.
Inhibition of the mitochondrial retrograde response by
overexpressing its negative regulatorMks1 enhanced α-synuclein-
triggered growth deficits (Yeger-Lotem et al., 2009). In con-
trast, overexpression of HAP4, encoding a transcriptional
activator of mitochondrial biogenesis genes, markedly suppressed
α-synuclein-triggered growth deficits (Yeger-Lotem et al., 2009).
Thus, the retrograde response and mitochondrial biogenesis
potentially play protective roles in cultures upon high levels of
α-synuclein, whereas mitophagy potentially exert a lethal func-
tion. Further studies are needed to discriminate the distinct roles
of these different mitochondrial quality control mechanisms in
modulating α-synuclein-triggered cytotoxicity.
Dissecting mitochondrial roles in other yeast PD models remains a
future task
Yeast cultures expressing fragments of the PD-associated GTPase
and protein kinase Lrrk2 demonstrated cytotoxicity as man-
ifested as growth deficits (Xiong et al., 2010). Expression of
the GTPase domain was sufficient to induce Lrrk2-triggered
cytotoxicity (growth assays) (Xiong et al., 2010) (Table 1). PD-
associated mutant variants with altered GTPase activity demon-
strated markedly increased cytotoxicity when compared with
cultures expressing wild-type GTPase fragments, underlining the
notion that altered GTPase activity of Lrrk2 is an important factor
determining neuronal cell loss during PD progression (Gloeckner
et al., 2006; Xiong et al., 2010). Remarkably, expression of Lrrk2
GTPase variants resulted in a significant increase in autophagic
vacuoles in yeast, and deletion of GCN4, encoding a transcrip-
tional activator of autophagy genes, led to a marked decrease in
Lrrk2-triggered cytotoxicity (growth assays) (Xiong et al., 2010).
These data suggest that, like in yeast cells expressing α-synuclein,
autophagy potentially plays detrimental roles in Lrrk2-induced
cytotoxicity. However, whether mitophagy and mitochondrial
damage are important inmodulating Lrrk2-triggered cytotoxicity
in yeast remain to be explored.
Expression of the vacuolar protein Ypk9 (yeast PARK9), the
yeast homolog of the PD-associated lysosomal ATPase ATP13A2,
suppressed α-synuclein-triggered cytotoxicity (growth assays) in
yeast (Gitler et al., 2009) (Table 1). Ypk9 expression increased
the cellular tolerance against elevated levels of manganese, which
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is an environmental risk factor for PD (Gitler et al., 2009). In
contrast, deletion of YPK9 resulted in cells demonstrating hyper-
sensitivity against manganese treatment (growth assays) (Gitler
et al., 2009; Chesi et al., 2012). This hypersensitivity was exe-
cuted, at least in part, by functional mitochondria, as evidenced
by the suppression of manganese-triggered cytotoxicity in yeast
strains lacking genes encoding mitochondrial proteins, such as
the GTPase Mgm1 and mitochondrial ribosomal proteins (Chesi
et al., 2012). Further studies will have to show, whether Ypk9
expression prevents pivotal mitochondrial damage and aberrant
mitophagy upon expression of α-synuclein.
The S. cerevisiae genome contains four homologs (HSP31,
HSP32, HSP33, and SNO4 (HSP34)) of the PD-associated gene
DJ-1 (Skoneczna et al., 2007). Deletion ofHSP31 led to increased
levels of ROS and to hypersensitivity against oxidative stress inde-
pendent of the respiratory competence of the yeast strains (clono-
genic survival assays) (Skoneczna et al., 2007). The cellular levels
of Hsp31 were increased upon stress, dependent on the oxidative
stress response transcription factor Yap1 (Skoneczna et al., 2007).
These data suggest that Hsp31 is an oxidative stress-induced chap-
erone that ameliorates cytotoxicity elicited by elevated levels of
ROS. Although Hsp31 expression did not relieve Lrrk2-triggered
cytotoxicity in yeast (growth assays) (Xiong et al., 2010), it is of
interest whether Hsp31 is able to modulate cytotoxicity elicited
by α-synuclein expression.
Yeast PD models may be used to elucidate the role of diverse
mitochondrial quality control mechanisms in modulating
cytotoxicity and cell death
Mitochondrial dysfunction is a common mechanism underly-
ing the pathogenesis of both sporadic and familiar forms of PD
(Correia et al., 2012). In PD patients and animal PD models,
activities of complex I of themitochondrial respiratory chain were
significantly decreased (Correia et al., 2012). The importance of
complex I deficiency can be estimated by the fact, that pharma-
ceutical treatment of animal models and humans with complex I
inhibitors, including MPTP and rotenone, was sufficient for the
loss of dopaminergic neurons, and consequently elicited clini-
cal symptoms typical for PD (Correia et al., 2012). S. cerevisiae
cannot be used as model for analyzing complex I dysfunction,
because it lacks a complex I ortholog (Li et al., 2006). Instead three
enzymes, one internal NADH dehydrogenase (Ndi1), and two
external NADH dehydrogenases (Nde1 and Nde2), accomplish
the function of mammalian complex I (Li et al., 2006). Notably,
yeast Ndi1 can fully complement complex I deficiency in mam-
malian cells, and therefore Ndi1 expression has been suggested to
cure complex I dysfunction in PD patients (Marella et al., 2009).
Consistent to the mentioned complex I deficiency, mtDNA
encoded defects, increased levels of ROS, and a decrease in the
mitochondrial membrane potential could be observed in PD
patients, animal and cell culture PDmodels (Correia et al., 2012).
The observed increased susceptibility for mitochondrial perme-
abilization points to mitochondrion-specific cell death (Correia
et al., 2012). In yeast cells expressing α-synuclein, increased levels
of mitochondrially produced ROS (Flower et al., 2005; Büttner
et al., 2008; Su et al., 2010), decreased mitochondrial mem-
brane potential (Lee et al., 2008), and release of Cyt. c into the
cytosol were observed (Flower et al., 2005). These data suggest
that aberrant mitochondrial respiratory chain activities lead to
ROS production and mitochondrial permeabilization in yeast,
i.e., similar events that occur in PD patients.
Increased mitochondrial degradation via mitophagy was
observed in PD patients and animal PD models (De Castro et al.,
2011). Notably, the PD genes encoding PINK1 and parkin pro-
mote mitophagy of damaged mitochondria (Geisler et al., 2010;
Springer and Kahle, 2011; Jin and Youle, 2012). PINK1 is a
mitochondrial kinase, which serves as a sensor of damaged and
depolarized mitochondria. In healthy mitochondria, PINK1 is
imported into the organelles, whereas in depolarized mitochon-
dria it rapidly accumulates at the mitochondrial outer membrane
with its kinase domain facing to the cytosol. Here, it recruits the
E3 ligase parkin, which ubiquitylates the mitochondrial fusion
proteins mitofusin 1 and 2, initiating mitochondrial fragmenta-
tion and mitophagy. Since PD-associated mutations of PINK1
and parkin interrupted this pathway, these data suggest that in
PD the accumulation of damagedmitochondria due to an impair-
ment of mitophagy contributes to PD pathogenesis (Geisler et al.,
2010). This model is underlined by the fact that PD-associated
mutations in the PD gene encoding ATP13A2 also resulted in
lysosomal dysfunction, which also impairs autophagic pathways
(Dehay et al., 2012).
Whereas in mammalian PD models, mitophagy appears to
play a beneficial role, the data observed in yeast PD models sug-
gest for a lethal function of mitophagy: mitophagy is lethal during
cell death upon expression of α-synuclein in yeast (Sampaio-
Marques et al., 2012), and the expression of Lrrk2 fragments in
yeast triggered a marked increase in autophagic vacuoles hint-
ing to a disturbance of autophagic processes (Xiong et al., 2010).
Future studies will be needed to address the obvious discrepancy
between the data obtained in mammalian and yeast PDmodels. It
is tempting to speculate that, in the first instance, mitophagy plays
as per se cytoprotective role by removing damaged mitochondria,
which can be very harmful for cell survival. However, it is think-
able that upon overload of this pathway, the process of mitophagy
may get inefficient and cytotoxic. In an alternative scenario, the
efficiency of mitophagy may be too high, and as consequence
too many healthy mitochondria are removed from the cell. Yeast
cells could tolerate a severe loss of healthy mitochondria, because
they can easily switch from respiration to fermentation. However,
since neurons essentially depend on high rates of respiration, they
would severely suffer from the loss of healthy mitochondria.
HUNTINGTON DISEASE (HD)
HD is an autosomal dominant neurodegenerative disorder char-
acterized by a progressive loss of neurons in the striatum and
the cortex with a consequent decline of cognitive and motor
functions (Ross and Tabrizi, 2011). HD is caused by an abnor-
mal polyglutamine (polyQ) expansion in the protein huntingtin
due to an aberrant CAG codon expansion in the exon 1 of the
gene encoding huntingtin (Ross and Tabrizi, 2011). This results
in an aggregation-prone protein eventually triggering cytotoxic-
ity and neuronal cell loss (Ross and Tabrizi, 2011). Increasing the
length of the polyQ expansion accelerates aggregation of hunt-
ingtin and strictly correlates with the increase in cytotoxicity and
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the decrease in disease onset (Ross and Tabrizi, 2011). In order
to dissect underlying mechanisms, various disease HD models
have been established, comprising transgenic HD mouse, mam-
malian cell culture, and yeast (Bossy-Wetzel et al., 2008; Mason
and Giorgini, 2011; Ross and Tabrizi, 2011; Correia et al., 2012).
Expression of disease-associated huntingtin in yeast results in
cytotoxicity, cell death, and critical mitochondrial damage
Yeast HD models expressing GFP-fusion constructs of exon 1 of
human huntingtin comprising various lengths of polyQ expan-
sion were generated (Meriin et al., 2002; Duennwald et al.,
2006; Solans et al., 2006; Ocampo et al., 2010). PolyQ con-
structs encoding 103 glutamine residues (103Q) efficiently trig-
gered growth deficits and apoptotic cell death (Sokolov et al.,
2006; Solans et al., 2006; Ocampo et al., 2010) (Table 1). In con-
trast, polyQ constructs encoding 25 glutamine residues (25Q)
remained nontoxic, and the constructs with intermediate polyQ
lengths showed intermediate cytotoxicity (Sokolov et al., 2006;
Solans et al., 2006; Ocampo et al., 2010). Upon 103Q expression,
the mitochondrial network disrupted, the mitochondrial mem-
brane potential dissipated, the mitochondrial protein synthesis
efficiency decreased, correlated with markedly reduced respira-
tory rates and defective energetic coupling (Solans et al., 2006;
Ocampo et al., 2010). The defects in respiratory capacity were
a result of impaired activities and decreased steady-state lev-
els of the respiratory chain complexes II and III (Solans et al.,
2006). As consequence of the impairment of the respiratory
chain increased ROS levels were observed (Sokolov et al., 2006;
Solans et al., 2006). Treatment with the antioxidants α-tocopherol
and resveratrol relieved the level of mitochondrial fragmenta-
tion and reduced respiratory impairment, but failed to decrease
cytotoxicity (growth assays) or increase cell survival (Sokolov
et al., 2006; Solans et al., 2006). These data suggest that ROS
are not essential for cell death but may accelerate cytotoxic-
ity in a vicious cycle by damaging the iron-sulfur clusters of
the respiratory chain, which are very susceptible for oxidative
damage, culminating in the production of increased ROS levels
(Solans et al., 2006). Mitochondria isolated from yeast cultures
expressing polyQ (103Q) demonstrated altered osmotic prop-
erties and facilitated mitochondrial permeabilization (Ocampo
et al., 2010), which is characteristic formitochondrion-dependent
cell death in yeast and mammalian cells (Galluzzi et al., 2009;
Guaragnella et al., 2012). Thus, critical mitochondrial dam-
age upon polyQ expression in yeast induces mitochondrion-
dependent cell death.
Critical mitochondrial damage in yeast HD models is due to direct
and indirect mechanisms
Some polyQ aggregates directly interacted with mitochondria
(Solans et al., 2006) and polyQ domains localized to the mito-
chondrial outer membrane (Ocampo et al., 2010). PolyQ aggre-
gates sequestered the mitochondrial proteins Ilv5, which is
involved in mtDNA maintenance, Atp2, which is a component
of complex V of the mitochondrial respiratory chain, and Ptk1,
a mitochondrial protein kinase (Wang et al., 2009). These data
suggest that at least part of polyQ-triggered cytotoxicity is due
to a direct damage of mitochondria (Mason and Giorgini, 2011).
In addition, polyQ-triggered cytotoxicity could impair mitochon-
dria in more indirect pathways. For instance, polyQ expression
resulted in destabilization of the actin cytoskeleton (Solans et al.,
2006), which is in yeast essential for mitochondrial motility
and the maintenance of the mitochondrial network, and there-
fore is pivotally linked with mitochondrial function (Frederick
and Shaw, 2007). PolyQ expression also drastically impaired the
ubiquitin-dependent ER-associated protein degradation pathway
(ERAD) by sequestering the pivotal ERAD components Cdc48
and Npl4 (Duennwald and Lindquist, 2008). This resulted in
the induction of the unfolded protein response and ER stress
(Duennwald and Lindquist, 2008). Since ER and mitochondria
are physically and functionally linked, e.g., the ER is pivotally
involved in the turnover of phospholipids to and from the mito-
chondrial membranes (Fujimoto and Hayashi, 2011), ERAD
dysfunction due to polyQ expression may indirectly result in
the damage of mitochondrial membranes (Braun and Zischka,
2008). Recently, a new ubiquitin-dependent protein quality con-
trol mechanism on the mitochondrial outer membrane was iden-
tified (Heo et al., 2010; Taylor and Rutter, 2011). This so-called
mitochondrion-associated protein degradation pathway (MAD)
shares the components Cdc48 and Npl4 with the ERAD path-
way (Heo et al., 2010; Taylor and Rutter, 2011). Therefore, it is
tempting to speculate that polyQ expression also impairs MAD,
culminating in a more direct damage of the mitochondrial outer
membrane.
Stimulation of mitochondrial biogenesis and repair pathways can
cure critical mitochondrial damage and cytotoxicity in yeast HD
models
Overexpression of HAP4, encoding the catalytic subunit of the
transcriptional activator complex triggering mitochondrial bio-
genesis, reduced growth deficits upon polyQ expression, ame-
liorated the cellular respiratory defects, restored mitochondrial
membrane potential, and increased mitochondrial protein trans-
lation efficiency (Ocampo et al., 2010). Expression of polyQ in
three different knock-out strains, which relieved polyQ-triggered
cytotoxicity (growth assays), resulted in the induction of the gene
encoding D-lactate dehydrogenase (Dld3) (Tauber et al., 2011).
In contrast, expression of polyQ in a yeast strain deleted for the
peroxisomal citrate synthase (Cit2) dramatically increased polyQ-
triggered cytotoxicity (growth assays) (Willingham et al., 2003).
Both Dld3 and Cit2 are induced uponmitochondrial damage and
are part of the retrograde response, which is a cellular defense
mechanism to counteract mitochondrial damage (Liu and Butow,
2006). Therefore, the mitochondrial retrograde response and
mitochondrial biogenesis could play protective roles in relieving
mitochondrial damage and polyQ-triggered cytotoxicity.
Mitochondrion-associated metabolites contribute to cytotoxicity in
yeast HD models
A genome-wide loss-of-function suppressor screen, in which
gene deletions were identified, that suppress cytotoxicity
of polyQ (growth assays), resulted in the identification of
another mitochondrion-associated pathway, modulating polyQ-
triggered cytotoxicity (Giorgini et al., 2005). Deletion of the
BNA4 gene, encoding the mitochondrial enzyme kynurenine
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3-monooxygenase, involved in the kynurenine pathway of tryp-
tophan degradation and NAD+ synthesis, resulted in the most
potent suppression of polyQ-triggered cytotoxicity (growth
assays) (Giorgini et al., 2005). Whereas bna4 cells lacked the
intermediates 3-hydroxykynurenine and quinolinic acid of the
kynurenine pathway, wild-type cells expressing polyQ accumu-
lated these metabolites and induced expression of enzymes of the
kynurenine pathway (Giorgini et al., 2005, 2008; Tauber et al.,
2011). Treatment of polyQ-expressing yeast cells with an inhibitor
of Bna4 reduced the levels of the metabolites and reduced
polyQ-triggered cytotoxicity (growth assays) and ROS produc-
tion (Giorgini et al., 2005). Consistently, 15 of the 28 identified
yeast knock-out strains, which suppressed polyQ-triggered cyto-
toxicity (growth assays), demonstrated significantly decreased
levels in 3-hydroxykynurenine and quinolinic acid (Giorgini et al.,
2008). These data indicate that accumulation of these metabolites
contributes to polyQ-triggered cytotoxicity (Mason and Giorgini,
2011). However, how accumulation of these metabolites triggers
mitochondrial damage remains unknown.
Yeast HD models recapitulate mitochondrial respiratory and
metabolic defects
Expression of disease-associated huntingtin is associated with
critical mitochondrial dysfunction in HD patients, in trans-
genic murine and mammalian cell culture HD models (Bossy-
Wetzel et al., 2008; Ross and Tabrizi, 2011; Correia et al., 2012).
Bioenergetic defects, impaired activity of the respiratory chain
complexes II and III, depolarization of mitochondrial mem-
brane potential, fragmentation of the mitochondrial network,
high levels of oxidative stress, and accumulation of the intermedi-
ates 3-hydroxykynurenine and quinolinic acid of the kynurenine
pathway are characteristic for the progression of HD (Reynolds
and Pearson, 1989; Bossy-Wetzel et al., 2008; Ross and Tabrizi,
2011; Correia et al., 2012). Since these hallmarks could also be
identified in yeast HD models, yeast appears to be an appropriate
model organism to elucidate pathological mechanisms on mito-
chondria upon polyQ-triggered cytotoxicity. Further key findings
in yeast are that the stimulation of mitochondrial biogenesis
and repair pathways and genetic and pharmacological manipula-
tion of the kynurenine pathway can markedly relieve cytotoxicity
upon polyQ expression. Indeed, transcriptional regulation of the
kynurenine pathway and its role in modulating cytotoxicity upon
polyQ expression is very similar in yeast and in transgenic HD
mouse models (Giorgini et al., 2008; Campesan et al., 2011;
Zwilling et al., 2011). Therefore, yeast may facilitate the discov-
ery of pathological pathways, which can be exploited for new
therapeutic approaches for HD treatment.
In yeast HDmodels, mitochondrion-dependent molecular cell
death could be discriminated between Cyt. c-, apoptosis-inducing
factor-, and endonuclease G-dependent or alternative scenarios.
Further, yeast HDmodels could be applied for elucidating the role
of mitochondrial fusion, fission, morphology and motility, and
for describing the maintenance of mtDNA. Mitochondrial per-
mabilization concomitant with mitochondrion-dependent cell
death and damage of mtDNA are hallmarks of HD (Bossy-Wetzel
et al., 2008; Correia et al., 2012). Inhibiting mitochondrial fission
and promoting mitochondrial fusion has recently been described
to relieve polyQ-triggered cytotoxicity in mammalian cells (Song
et al., 2011). Therefore, a more detailed analysis in yeast HDmod-
els could be helpful for better understanding the roles of these
conserved pathways in HD.
Autophagy is involved in the degradation of huntingtin aggre-
gates (Qin et al., 2003), and mitophagy has been described to
occur in immortalized cell lines from HD patients (Mormone
et al., 2006). Different huntingtin domains demonstrate homol-
ogy to the yeast autophagy proteins Atg23, Vac8, and Atg11,
raising the question whether huntingtin itself is involved in
autophagy/mitophagy regulation (Steffan, 2010). Therefore, ana-
lyzing the role of mitophagy in modulating polyQ-triggered
cytotoxicity in yeast is also of high interest.
AMYOTROPHIC LATERAL SCLEROSIS (ALS)
ALS is a frequent degenerative motor neuron disease character-
ized by adult-onset loss of the lower and upper motor neuron
systems, resulting in muscle weakness and wasting (Andersen and
Al-Chalabi, 2011). Mutations in 13 different genes are causative
for hereditary forms of ALS (Andersen and Al-Chalabi, 2011;
Wu et al., 2012), and even more genes are putatively associated
with ALS (Andersen and Al-Chalabi, 2011). The most common
ALS-associated genes are SOD1, TARDBP, and FUS, encoding the
ROS-scavenger enzyme superoxide dismutase 1 (SOD1), and the
RNA-binding proteins TDP-43 and FUS/TLS (Andersen and Al-
Chalabi, 2011). ALS-associated variants of these proteins demon-
strate mislocalization and/or a high tendency for aggregation
(Andersen and Al-Chalabi, 2011; Da Cruz and Cleveland, 2011).
Yeast models expressing ALS-associated wild-type and mutant
SOD1, TDP-43, and FUS/TLS have been established to further
analyze the detrimental roles of these proteins on cell survival
(Bastow et al., 2011).
ALS-associated mutant Sod1 variants demonstrate increased
mitochondrial localization and impair mitochondrial respiratory
chain activity
Yeast cells lacking SOD1, the ortholog of human SOD1, are
sensitive against oxidative stress (growth assays), highlighting
the role of Sod1 as superoxide scavenger (Bastow et al., 2011).
Sod1 is also involved in the assembly of iron-sulfur clusters,
which are important for enzymes of the respiratory chain, the
TCA cycle, and amino acid biosynthetic pathways (Strain et al.,
1998; Wallace et al., 2004; Sehati et al., 2011). Sod1 demon-
strates dual localization between the cytosol, where the vast
majority of Sod1 is localized, and the mitochondrial intermem-
brane space (Klöppel et al., 2010). Surprisingly, expression of
ALS-associated mutant (G93A) Sod1 in yeast resulted in an
increased mitochondrial localization and an increased tolerance
against mitochondrially produced ROS (Klöppel et al., 2010)
(Table 1). Notably, a decrease in electron transport in the mito-
chondrial respiratory chain was observed upon expression of
ALS-associated mutant (G93A) Sod1 (Gunther et al., 2004).
Therefore, it is tempting to speculate that increased mitochon-
drial localization of Sod1 disturbs the mitochondrial respiratory
chain, and that this mechanism contributes to cell loss (Bastow
et al., 2011). Both activation and mitochondrial localization of
Sod1 depend on the copper chaperone Ccs1, which demonstrates
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high sequence identity with human SOD1 (Leitch et al., 2009;
Groß et al., 2011; Klöppel et al., 2011). ALS-associated mutant
Sod1 variants were rapidly degraded in yeast cells lacking CCS1
(Carroll et al., 2006), underlining the assumption that their
mitochondrial localization is important for their detrimental
action.
Expression of TDP-43 and FUS/TLS are cytotoxic in yeast, and
mitochondrial respiratory capacity plays a pivotal role in
modulating TDP-43-triggered cytotoxicity
Expression of wild-type and disease-associated mutant variants
of TDP-43 and FUS/TLS triggered cytoplasmic protein aggrega-
tion leading to growth deficits, loss of clonogenic survival, and
apoptosis and necrosis in yeast (Johnson et al., 2008, 2009; Elden
et al., 2010; Armakola et al., 2011; Braun et al., 2011; Couthouis
et al., 2011; Fushimi et al., 2011; Ju et al., 2011; Kryndushkin
et al., 2011; Robinson, 2011; Sun et al., 2011) (Table 1). TDP-43-
expressing yeast cells showed an age-dependent loss of clonogenic
survival concomitant to ROS accumulation (Johnson et al., 2008;
Braun et al., 2011). Mitochondria play a pivotal role in execut-
ing TDP-43-triggered cell death (clonogenic survival assays): (1)
Cytotoxicity was significantly decreased in cells lacking mtDNA
and functional mitochondria, (2) impairment of the respiratory
chain relieved cytotoxicity with a stringent correlation between
cytotoxicity and the degree of respiratory capacity or mtDNA
stability, and (3) increasing the respiratory capacity enhanced
TDP-43-triggered ROS production and cell death (Braun et al.,
2011). Mitochondrion-dependent cell death was independent of
the mitochondrial cell death proteins apoptosis-inducing fac-
tor, endonuclease G, and Cyt. c, suggesting that an alterna-
tive mitochondrion-dependent cell death pathway may be active
(Braun et al., 2011).
Whether FUS/TLS-triggered cytotoxicity is also modulated by
mitochondrial function is still an open question. However, in a
genome-wide screen to identify modulators of FUS/TLS-triggered
cytotoxicity (growth assays) upon overexpression or deletion, sev-
eral mitochondrion-associated candidate genes were identified
(Sun et al., 2011). Yeast strains deleted for genes encoding com-
ponents of the mitochondrial protein translation machinery, the
mitochondrial respiratory chain, and the TCA cycle increased
FUS/TLS-triggered cytotoxicity (growth assays) (Sun et al., 2011).
These data suggest that impaired mitochondria upon deletion of
these genes are more vulnerable against FUS/TLS expression, and
raise the possibility that mitochondrial damage contributes to the
execution of FUS/TLS-triggered cytotoxicity.
Yeast ALS models may support and complement hypotheses
obtained in higher model systems
Structural mitochondrial abnormalities as seen in electron
microscopy and markers of oxidative stress were observed in
ALS patients, and in mouse models expressing ALS-associated
mutant variants of SOD1 and TDP-43 (Martin, 2011; Cozzolino
et al., 2012). In ALS patients with SOD1 etiology Cyt. c release
correlated with apoptosis, and in mouse ALS models for SOD1-
associated ALS, mitochondrial permeabilization correlated with
necrosis (Martin, 2011). These data hint to the induction of
mitochondrion-specific cell death during ALS. In yeast, expres-
sion of TDP-43 triggered oxidative stress, and apoptosis and
necrosis, and mitochondrial respiration was found to be an
important modulator of cytotoxicity (clonogenic survival assays)
(Braun et al., 2011). Thus, the determination and critical com-
parison of cell death pathways in yeast cells expressing ALS-
associated wild-type and mutant SOD1, TDP-43, and FUS/TLS
may help to elucidate common and distinct mechanisms under-
lying cytotoxicity and mitochondrion-dependent cell death with
potential relevance for ALS.
Abnormally aggregated mitochondria, as seen in mouse mod-
els for TDP-43 and FUS/TLS-mediated ALS, suggest for deficits
in mitochondrial trafficking in motor neurons, a phenomenon
which has already been proven in mouse models expressing
ALS-associated mutant SOD1 (Martin, 2011; Cozzolino et al.,
2012). Expression of ALS-associated mutant SOD1, TDP-43,
and FUS/TLS triggered mitochondrial fragmentation in mouse
motor neurons, suggesting a further role of the mitochon-
drial fusion/fission balance inmodulating pathogenesis (Magrane
et al., 2009, 2012; Xu et al., 2010, 2011; Cozzolino et al.,
2012; Tradewell et al., 2012). The mechanisms of mitochondrial
fusion/fission are conserved from humans to yeast (Westermann,
2010). Therefore, yeast ALS models may help to dissect com-
ponents of the mitochondrial fusion/fission machinery, which
pivotally contribute to the modulation of cytotoxicity. In con-
trast, for analyzing the role of mitochondrial trafficking in ALS
pathology, yeast ALS models might be of limited use, because the
mitochondrial trafficking in yeast depends on the actin cytoskele-
ton, whereas neuronal mitochondria are transported along the
microtubule cytoskeleton (Frederick and Shaw, 2007).
ALS-associated mutant SOD1 demonstrated increased mito-
chondrial association, which is correlated with elevated ROS
production and pathology (Martin, 2011; Cozzolino et al., 2012).
In contrast, mitochondrial aggregates in mouse models express-
ing TDP-43 and FUS/TLS did not contain the disease-causing
proteins, suggesting that the detrimental effects of these proteins
for mitochondria are rather indirect (Xu et al., 2010; Cozzolino
et al., 2012). Consistent to the observations in mouse models,
ALS-associated mutant (G93A) SOD1 demonstrated increased
localization in the mitochondrial intermembrane space in yeast
(Klöppel et al., 2010), with potential harmful effects for mito-
chondrial respiratory chain efficiency (Gunther et al., 2004).
Due to the extensive knowledge on the regulation of mito-
chondrial import of SOD1 in yeast (Leitch et al., 2009; Groß
et al., 2011; Klöppel et al., 2011), yeast might be a good model
to elucidate molecular components and pathways involved in
SOD1 pathology. In yeast, TDP-43 aggregates demonstrated a
peri-mitochondrial localization, although a strong interaction
between TDP-43 andmitochondria could not be observed (Braun
et al., 2011). These data suggest that in yeast, as in humans, indi-
rect effects may contribute to the pivotal mitochondrial damage.
The elucidation of these mechanisms of mitochondrial damage
will be one interesting future task.
OTHER NEURODEGENERATIVE DISORDERS
Polyalanine (polyA) disorders are associated with trinucleotide
repeat expansions in genes involved in developmental processes,
including central nervous system development (ZIC2), neural
development (SOX3), and cerebral development and patterning
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(ARX) (Messaed and Rouleau, 2009). The trinucleotide repeat
expansions encode abnormal polyA expansions causing pro-
tein aggregation and neuronal loss, and therewith triggering
neurodegenerative diseases, such as holoprosencephaly, X-linked
hypopituitarism, and X-linked mental retardation (Messaed and
Rouleau, 2009). Recently, a yeast model for polyA-triggered cyto-
toxicity has been established (Konopka et al., 2011). With increas-
ing length of the polyA stretches, cytotoxicity markedly increased,
as measured by growth deficits and decreased plasma membrane
integrities (Konopka et al., 2011). Whether mitochondria are
affected and pivotally involved in polyA-triggered cytotoxicity in
yeast remains unknown. However, mitochondrial dysfunction,
the formation of the mitochondrial permeability transition pore,
Cyt. c release, and the translocation of pro-apoptotic BAX to
mitochondria have been observed in mammalian polyA models
(Toriumi et al., 2008, 2009; Bhattacharjee et al., 2012). Therefore,
it might be a fruitful approach to dissect the role of mitochondria
in polyA-triggered cytotoxicity in yeast.
Prion disorders are fatal neurodegenerative conditions char-
acterized by the conversion of the soluble cellular protein PrPC
into its insoluble and infectious prion form PrPSc (Imran and
Mahmood, 2011). For instance in Creutzfeld-Jakob disease, PrPSc
accumulation results in neuronal loss causing rapid progres-
sive dementia and cerebellar dysfunction (Imran and Mahmood,
2011). Yeast models have been established expressing mammalian
PrPC (Li and Harris, 2005; Bounhar et al., 2006; Halfmann et al.,
2010; Josse et al., 2012). PrPC expression was not cytotoxic for
yeast cells (Li and Harris, 2005; Bounhar et al., 2006). In contrast,
PrPC expression suppressed yeast cytotoxicity triggered by the
expression of the mammalian pro-apoptotic BAX, as measured by
growth assays, clonogenic survival assays, and assays measuring
metabolic activities (Li and Harris, 2005; Bounhar et al., 2006).
Consistently, PrPC expression prevented BAX-induced cell death
in primary neuronal cultures (Bounhar et al., 2001). Since BAX
triggers mitochondrion-dependent cell death in mammalian cells
and in yeast (Khoury and Greenwood, 2008), these data sug-
gest that PrPC plays a protective role in preventing mitochondria
from executing cell death (Li and Harris, 2005; Bounhar et al.,
2006).
CONCLUSIONS AND OUTLOOK
Mitochondrial damage and dysfunction are hallmarks of AD,
PD, HD, and ALS (Martin, 2011; Correia et al., 2012; Cozzolino
et al., 2012). Yeast models for the elucidation of mechanisms of
cytotoxicity and cell death upon expression of AD-, PD-, HD-,
and ALS-associated proteins have been established (Gitler, 2008;
Miller-Fleming et al., 2008; Winderickx et al., 2008; Bharadwaj
et al., 2010; Braun et al., 2010; Khurana and Lindquist, 2010;
Bastow et al., 2011; De Vos et al., 2011; Mason and Giorgini,
2011). In these models mitochondrial (dys)function contributes
to cytotoxicity. The description ofmitochondrial damage, the elu-
cidation of mitochondrion-specific cell death pathways, and the
dissection of the roles of mitochondrial quality control mecha-
nisms, including mitochondrial dynamics and degradation, has
just initiated in these yeast models. Therefore, neurotoxic yeast
models will elucidate novel paradigms of mitochondrial pathobi-
ology, which can be easily validated in other model organisms for
neurodegenerative disorders.
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